SMi presents the 13th annual industry leading conference: Cold Chain Distribution

SMi Group10 - 11 December 2018, London, UK.
The 13th annual event will specifically focus on recent advances in temperature-controlled logistic solutions and the impact of regulatory changes on this multi-billion-dollar industry. The event will also address the impact of the overwhelming digitalisation of the industry and how companies, from biotech’s to pharma, need to adapt, as well as the crucial challenges of supply chain visibility and data integrity in the cold chain industry.

The two-day event will also look at various developments within the industry, guiding companies on how best to ensure costs are kept low, and quality remains high, whilst simultaneously staying compliant to global regulations.

This year's event will continue to lead with its unrivalled panel of experts bringing you the most insightful presentations and issues in the field of temperature-controlled distribution.

Chairs for 2018

  • Bob Hayes, Director, SeerPharma (UK)
  • Tony Wright, CEO, Exelsius

Featured Speakers

  • Bob Hayes, Director, SeerPharma (UK)
  • Stephen Mitchell, Quality Lead Logistics Partnerships, GSK
  • GianneOlaes-Dénis, Supply Chain Quality Manager, SanofiGenzymeEurope
  • Stefan Braun, Managing Director, SmartCAE
  • GianpieroLorusso, Director, Supply Operations and GS, Merck
  • Francicso Rizzuto, Cargo Specialist, Manager for Europe, IATA
  • Marco Gaudesi, Pharmacist - GDP and Cold Chain Referent, MSF
  • Henk Mulder, Head, Digital Cargo, IATA

Key Highlights

  • Evaluate the current GDP guidelines, with reference to the recently published PQG/ECA guide and discover the implications for everyday practice
  • Explore the overwhelming digitalisation of the supply chain and identify the subsequent security issues involved
  • Discover the temperature-controlled logistic solutions to best optimize your supply chain
  • Discuss the technical agreements within the supply chain and find out what questions you should be asking
  • Identify the challenges for the supply chain within emerging markets and discover the best solutions for optimization of your process

View the full agenda online: www.coldchain-distribution.com

  • Register by 29th June and save £400
  • Register by 28th September and save £300
  • Register by 31st October and save £200

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Most Popular Now

How SARS-CoV-2 mutates to escape antibody binding

In a recurring pattern of evolution, SARS-CoV-2 evades immune responses by selectively deleting small bits of its genetic sequence, according to new research from the Uni...

Early functional SARS-COV-2 specific T cell respon…

Humoral and cellular adaptive immunity are two immune mechanisms that act against pathogens. Humoral immunity is mediated by antibodies, while cellular immunity does not ...

Anticancer drug may improve outcome for severe COV…

Treating severe COVID-19 patients with the anticancer drug bevacizumab may reduce mortality and speed up recovery, according to a small clinical study in Italy and China ...

One dose of COVID-19 vaccine provokes strong immun…

Although clinical trial data are encouraging, real-world evidence with regard to the COVID-19 vaccine remains scarce. In particular, response to the vaccine among those p...

Johnson & Johnson announces submission of appl…

Johnson & Johnson (NYSE: JNJ) (the Company) announced that Janssen Biotech, Inc., has submitted an application to the U.S. Food and Drug Administration (FDA) requesting E...

CureVac initiates rolling submission with European…

CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today annou...

Pfizer and BioNTech publish data from in vitro stu…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the publication in Nature Medicine of data from in vitro studies that demonstrate that sera from in...

COVID-19 Vaccine AstraZeneca recommended for use i…

AstraZeneca's COVID-19 vaccine has been recommended for conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 c...

Roche announces the upcoming launch of the SARS-Co…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced it has obtained the CE mark for its new SARS-CoV-2 Rapid Antigen Test Nasal. The test will be available in countries acceptin...

Sinovac receives conditional marketing authorizati…

Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced that the China National Medical Produ...

A machine-learning approach to finding treatment o…

When the COVID-19 pandemic struck in early 2020, doctors and researchers rushed to find effective treatments. There was little time to spare. "Making new drugs takes fore...

Bayer to manufacture mRNA vaccine in Germany

In a joint press briefing today together with German Health Minister Jens Spahn, Minister-President of North Rhine-Westphalia, Armin Laschet, and Chief Executive Officer ...